# US 2026/0256822 A1 · Entry-modulating agents and uses therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0256822 A1
- Document ID: US20260256822A1
- Status: Published application
- Kind: A1
- Application number: 18/878,263
- Filed: 2023-06-26
- Published: 2026-09-03
- Earliest claimed: 2022-06-24
- Applicants: Griffith University; Swiss Tropical and Public Health Institute; Universitat Basel
- Inventors: Michael P. Jennings; Christopher J. Day; Gerd Pluschke
- Web page: https://patentgrep.com/patent/US20260256822A1

## CPC

- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 33/06: Antimalarials
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This disclosure relates generally to the use of compounds that inhibit binding of Plasmodium cysteine-rich protective antigen (CyRPA) to glycans of cells that are susceptible to infection by Plasmodium pathogens, including glycans terminating with α2-6-linked sialic acid, in methods, compositions and kits for inhibiting the interaction of a Plasmodium pathogen to Plasmodium-binding glycan-expressing cells, including α2-6-linked sialic acid-expressing cells such as erythrocytes, and for treating or inhibiting the development of malaria.

## Claims

### Claim 1

A method for inhibiting interaction of a Plasmodium cysteine-rich protective antigen (CyRPA) with a cell that is capable of being infected by a Plasmodium pathogen, the method comprising, consisting or consisting essentially of contacting the CyRPA with a ligand of the CyRPA which when bound to the CyRPA inhibits interaction of the CyRPA with the cell.

### Claim 2

A method for treating or inhibiting the development of a Plasmodium pathogen infection in a subject, the method comprising, consisting or consisting essentially of administering to the subject an effective amount of a ligand of a cysteine-rich protective antigen (CyRPA) expressed by the Plasmodium pathogen which ligand, when bound to the CyRPA, inhibits interaction of the CyRPA with a cell that is capable of being infected by the Plasmodium pathogen, to thereby treat or inhibit the development of the Plasmodium pathogen infection in the subject.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the CyRPA interacts with a glycan expressed by the cell when the CyRPA is not bound to the ligand and wherein when the CyRPA is bound to the ligand, the ligand inhibits interaction of the CyRPA with the glycan.

### Claim 4 (depends on 3)

The method of claim 3, wherein the glycan comprises an α2-6-linked sialic acid.

### Claim 5 (depends on 4)

The method of claim 4, wherein the glycan comprises α2-6-Neu5Ac.

### Claim 6 (depends on 4, 5)

The method of claim 4 or claim 5, wherein the glycan comprises α2-6-sialyllactosamine (Neu5Ac-α-(2-6)-Gal-β-(1-4)-GlcNAc).

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1 to 6, wherein the cell is an erythrocyte or hepatocyte.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the Plasmodium pathogen is a drug-resistant Plasmodium pathogen.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1 to 8, wherein the Plasmodium pathogen is a multidrug-resistant Plasmodium pathogen.

### Claim 10 (depends on 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 2 to 9, wherein the CyRPA ligand is administered concurrently with an ancillary agent (e.g., an antimalarial agent or adjunctive therapy for improving efficacy, or reducing one or more malarial disease-associated complications).

### Claim 11

A composition for use in therapy or prophylaxis of a Plasmodium pathogen infection in a subject, the composition comprising, consisting or consisting essentially of a ligand of a P. falciparum CyRPA which, when bound to the CyRPA, inhibits interaction of the CyRPA with an α2-6-linked sialic acid of an α2-6-linked sialic acid-expressing cell, and optionally a pharmaceutically acceptable carrier.

### Claim 12

A kit for use in treating a Plasmodium pathogen infection in a subject, the kit comprising: a ligand of a Plasmodium pathogen CyRPA which, when bound to the CyRPA, inhibits interaction of the CyRPA with an α2-6-linked sialic acid of an α2-6-linked sialic acid-expressing cell, and optionally instructional material for performing the treatment.

### Claim 13 (depends on 12)

The kit for use according to claim 12, further comprising an ancillary agent useful for the treatment of the Plasmodium pathogen infection (e.g., an antimalarial agent or adjunctive therapy for improving efficacy, or reducing one or more malarial disease-associated complications).

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1 to 10, or the composition of claim 11, or the kit for use of claim 12 or claim 13, wherein the CyRPA ligand is selected from the compounds listed in TABLE 1.
TABLE 1
1. A compound of formula (I):
(I)
(Zinc Pyrithione)
2. A compound of formula (II):
(II)
(Ivermectin)
3. A compound of formula (III):
(III)
(RIVANOL)

### Claim 15

A method for treating or inhibiting the development of a Plasmodium pathogen infection in a subject the method comprising, consisting or consisting essentially of administering to the subject an effective amount of a compound of formula (I):
to thereby treat or inhibit the development of the Plasmodium pathogen infection in the subject.

### Claim 16

A method for treating a Plasmodium pathogen infection in a subject the method comprising, consisting or consisting essentially of administering to the subject an effective amount of a compound of formula (II):

### Claim 17

A method for treating or inhibiting the development of a Plasmodium pathogen infection in a subject the method comprising, consisting or consisting essentially of administering to the subject an effective amount of a compound of formula (III):

### Claim 18 (depends on 15, 16, 17)

The method of any one of claims 15 to 17, wherein the Plasmodium pathogen is a drug-resistant Plasmodium pathogen, suitably a multidrug-resistant Plasmodium pathogen.

### Claim 19 (depends on 15, 16, 17, 18)

The method of any one of claims 15 to 18, comprising identifying the subject as being infected with a drug-resistant Plasmodium pathogen.

### Claim 20 (depends on 15, 16, 17, 18, 19)

The method of any one of claims 15 to 19, comprising administering the compound after the subject has been administered at least one antimalarial drug to which the Plasmodium pathogen is resistant.
